Bristol Myers Squibb expands Sotyktu label. Will TYK2 inhibition challenge biologics in psoriatic arthritis?

FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.